SRZN

Surrozen, Inc. [SRZN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SRZN Stock Summary

The Moving Average Convergence Divergence (MACD) for SRZN recently turned positive (within last 10 days).

Top 10 Correlated ETFs

SRZN

Top 10 Correlated Stocks

SRZN

In the News

SRZN Financial details

Company Rating

Market Cap

21.87M

Income

-28.45M

Revenue

12.5M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 May 2024

P/E

-11.36

Forward P/E

PEG

-6.2

P/S

1.73

P/B

7.1

P/C

P/FCF

-0.64

Quick Ratio

6.81

Current Ratio

7.25

Debt / Equity

LT Debt / Equity

EPS (TTM)

-14.14

EPS next Y

EPS next Q

EPS this Y

78.49%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

9.83%

SMA20

13.05%

SMA50

27.93%

SMA100

78.77%

Inst Own

Inst Trans

ROA

-53%

ROE

-47%

ROC

-0.81%

Gross Margin

100%

Oper. Margin

-306%

Profit Margin

-228%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

4.5-16.19

52W High

-1.56%

52W Low

+293.75%

RSI

63.26

Rel Volume

4.04

Avg Volume

17.58K

Volume

70.98K

Perf Week

19.32%

Perf Month

13.72%

Perf Quarter

67.55%

Perf Half Y

93.73%

Beta

0.742

Volatility

1.09%, 1.33%

Prev Close

1.35%

Price

15.75

Change

-1.81%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 17.58K
Market Capitalization 21.87M
Employee 74
CEO Mr. Craig C. Parker M.B.A.
Headquarters South San Francisco,CA,US
IPO Date 2021-01-11
Website https://www.surrozen.com

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.